Epidemiological, Clinical and Therapeutic Patterns of Venous Thromboembolic Disease in Cancer Patients Followed up in Two Reference Hospitals in Cameroon
Background:Cancer increases the incidence of venous thromboembolic disease (VTE), which represents a significant cause of morbidity, mortality, and economic burden in cancer patients. Objective: We aimed to describe the epidemiologic, clinical,?and therapeutic pattern of VTE in cancer patients followed-up in two reference hospitalsin Cameroon over?the past ten years. Methods: This was a cross-sectional retrospective study conducted in the oncology department of the General hospitals of Yaoundé and Douala. We included the medical records of all patients aged 18 years and above who had active cancer with a confirmed diagnosis of VTE from 2010 to 2021. Results: We analysed 408 patients’ medical records. The prevalence of VTE was 7.6%. All those having VTE had solid tumours. There were twenty (64.5%) cases of deep venous thrombosis, five (16.1%) cases of pulmonary embolism,?and three (9.7%) cases of both. Poor performance status and chemotherapy were independently associated with the development of VTE. Most of the patients were treated with compression stockings and low molecular weight heparin. Conclusion: VTE prevalence is high among cancer patients in Cameroon. It is most frequent in solid tumours originating from the genitourinary system, the lung, the pancreas,?and the brain.
References
[1]
Louw, V.J. and Ntusi, N.A.B. (2019) Virchow’s Triad Revisited. South African Medical Association, 109, 822-823.
https://doi.org/10.7196/SAMJ.2019.v109i11.14442
[2]
Riva, N., Donadini, M.P. and Ageno, W. (2015) Epidemiology and Pathophysiology of Venous Thromboembolism: Similarities with Atherothrombosis and the Role of Inflammation. Thromb Haemost, 113, 1176-1183.
https://doi.org/10.1160/TH14-06-0563
[3]
Metharom, P., Falasca, M. and Berndt, M.C. (2019) The History of Armand Trousseau and Cancer-Associated Thrombosis. Cancers, 11, Article 158.
https://doi.org/10.3390/cancers11020158
[4]
Geerts, W.H., Bergqvist, D., Pineo, G.F., Heit, J.A., Samama, C.M., Lassen, M.R., et al. (2008) Prevention of Venous Thromboembolism. Chest, 133, 132S-175S.
https://doi.org/10.1378/chest.08-0656
[5]
Wun, T. and White, R.H. (2009) Epidemiology of Cancer-Related Venous Thromboembolism. Best Practice & Research Clinical Haematology, 22, 9-23.
https://doi.org/10.1016/j.beha.2008.12.001
[6]
Khorana, A.A., Francis, C.W., Culakova, E., Kuderer, N.M. and Lyman, G.H. (2007) Frequency, Risk Factors, and Trends for Venous Thromboembolism among Hospitalised Cancer Patients. Cancer, 110, 2339-2346. https://doi.org/10.1002/cncr.23062
[7]
Blom, J.W., Doggen, C.J.M., Osanto, S. and Rosendaal, F.R. (2005) Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis. The Journal of the American Medical Association, 293, 715-722.
https://doi.org/10.1001/jama.293.6.715
[8]
Donnellan, E., Kevane, B., Bird, B.R.H. and Ni Ainle, F. (2014) Cancer and Venous Thromboembolic Disease: From Molecular Mechanisms to Clinical Management. Current Oncology, 21, 134-143. https://doi.org/10.3747/co.21.1864
[9]
Khorana, A.A., Francis, C.W., Culakova, E., Kuderer, N.M. and Lyman, G.H. (2007) Thromboembolism Is a Leading Cause of Death in Cancer Patients Receiving Outpatient Chemotherapy. Journal of Thrombosis and Haemostasis, 5, 632-634.
https://doi.org/10.1111/j.1538-7836.2007.02374.x
[10]
Ay, C., Dunkler, D., Marosi, C., Chiriac, A.-L., Vormittag, R., Simanek, R., et al. (2010) Prediction of Venous Thromboembolism in Cancer Patients. Blood, 116, 5377-5382. https://doi.org/10.1182/blood-2010-02-270116
[11]
Cronin-Fenton, D.P., Sondergaard, F., Pedersen, L.A., Fryzek, J.P., Cetin, K., Acquavella, J., et al. (2010) Hospitalisation for Venous Thromboembolism in Cancer Patients and the General Population: A Population-Based Cohort Study in Denmark, 1997-2006. British Journal of Cancer, 103, 947-953.
https://doi.org/10.1038/sj.bjc.6605883
[12]
Simanek, R., Vormittag, R., Ay, C., Alguel, G., Dunkler, D., Schwarzinger, I., et al. (2010) High Platelet Count Associated with Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Journal of Thrombosis and Haemostasis, 8, 114-120.
https://doi.org/10.1111/j.1538-7836.2009.03680.x
[13]
Jedy-Agba, E., Joko, W.Y., Liu, B., Buziba, N.G., Borok, M., Korir, A., et al. (2020) Trends in Cervical Cancer Incidence in Sub-Saharan Africa. British Journal of Cancer, 123, 148-154. https://doi.org/10.1038/s41416-020-0831-9
[14]
Mulder, F.I., Horváth-Puhó, E., van Es, N., van Laarhoven, H.W.M., Pedersen, L., Moik, F., et al. (2021) Venous Thromboembolism in Cancer Patients: A Population-Based Cohort Study. Blood, 137, 1959-1969.
https://doi.org/10.1182/blood.2020007338
[15]
Khorana, A.A., Kuderer, N.M., Culakova, E., Lyman, G.H. and Francis, C.W. (2008) Development and Validation of a Predictive Model for Chemotherapy-Associated Thrombosis. Blood, 111, 4902-4907. https://doi.org/10.1182/blood-2007-10-116327
[16]
Guven, D.C., Aksun, M.S., Sahin, T.K. et al. (2021) Poorer Baseline Performance Status Is Associated with Increased Thromboembolism Risk in Metastatic Cancer Patients Treated with Immunotherapy. Supportive Care in Cancer, 29, 5417-5423.
https://doi.org/10.1007/s00520-021-06139-3
[17]
Agnelli, G., Buller, H.R., Cohen, A., Gallus, A.S., Lee, T.C., Pak, R., et al. (2015) Oral Apixaban for the Treatment of Venous Thromboembolism in Cancer Patients: Results from the AMPLIFY Trial. Journal of Thrombosis and Haemostasis, 13, 2187-2191. https://doi.org/10.1111/jth.13153
[18]
Khorana, A.A., Noble, S., Lee, A.Y.Y., Soff, G., Meyer, G., O’Connell, C., et al. (2018) Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 16, 1891-1894. https://doi.org/10.1111/jth.14219